LEIDEN, Netherlands, Nov. 09, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that it has been selected by Euronext Indices B.V. (Euronext) as a candidate for inclusion in the Amsterdam Midkap index (AMX).
On November 4, 2005, Euronext released an indicative selection of companies for inclusion in the AEX, AMX and the AscX indices. Based on data currently available, Pharming is eligible for inclusion in the AMX index. Candidate selection is largely based on value of full year 2005 turnover of shares in euros. The definitive selection of companies to be included in the AMX index will be announced in January 2006 and will take effect on March 1, 2006.
Background on Pharming Group N.V.
Pharming Group N.V. is developing innovative protein products for unmet needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development -- recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for food use. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.